DISCLAIMERThe information and materials accessed through or made available for use on any of our Sites, including, any information about diseases, conditions, treatments, or medicines, are for informational purposes only. The Content is not intended to be and is not a substitute for professional medical advice, diagnosis, or treatment, and your participation on our Sites does not create a healthcare professional-patient relationship. You should consult a doctor or other qualified health care professional regarding any questions you have about your health or before making any decisions related to your health or wellness. Call your doctor or 911 immediately if you think you may have a medical emergency.
Trusted Resources: News & Events
Latest announcements and gatherings
The American Society of Hematology (ASH) is launching a sickle cell disease (SCD) clinical trials network in order to accelerate the development of new therapies for a patient community that has very few treatments and curative options.
The core activities of the network will include matching clinical trial sponsors with research sites, facilitating patient recruitment, and improving the efficiency of clinical trials by advising on optimal trial design and ensuring a coordinated approach across the network. The first study is expected to be initiated in the fall of 2019.
The network will be led by Charles “Chuck” Chesson, PhD, who was named as director in July of 2018. Dr. Chesson comes to ASH after nearly two decades at the public health research organization Social and Scientific Systems, where he most recently served as Group Vice President, Clinical Research and Bioscience.
news & eventsCIRM and NHLBI Collaborating to Fund Cell and Gene Therapies for Sickle Cell DiseaseThe California Institute for Regenerativ...
news & eventsSCDAA News Advisory: Partial Hold on Gene Therapy TrialOn December 20, the FDA placed a partial...
education & researchInterventions for preventing silent cerebral infarcts in people with sickle cell diseaseBACKGROUND: Sickle cell disease (SCD) i...
education & researchThe FDA Encourages New Treatments for Sickle Cell DiseaseThe FDA continues to work with stakehold...
news & eventsCRISPR could end sickle cell disease, but signing up black patients for clinical trials will be a hard sellThe first attempts to use a groundbreaki...
news & eventsGamida Cell Announces $3.5 Million Grant from the Israeli GovernmentGamida Cell, a leader in cellular and im...
news & eventsNHLBI Stepping Up Efforts to Apprise SCD Patients of Therapies and TrialsWide interest in a CBS 60 Minutes story ...
send a message
The cookie settings on this website are set to "allow cookies" to give you the best browsing experience possible. If you continue to use this website without changing your cookie settings or you click "Accept" below then you are consenting to this.
Support for this site is provided by
This platform is made possible through a partnership with the Sickle Cell Disease Association of America, Inc. (SCDAA) and its member organizations. SCDAA's mission is to advocate for people affected by sickle cell conditions and empower community-based organizations to maximize quality of life and raise public consciousness while advancing the search for a universal cure.